NCT04986514Visszavonva
Implementation of a Biological Sample Collection in Systemic Sclerosis Patients
Identification of Biomarkers Associated With Disease Worsening Within 10 Years in Scleroderma Patients
Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. máj. 4.
Megadott ok: withdrawed by the sponsor. A concurrent study is currently underway in the department
Rövid összefoglaló (regiszter, angolul)
Systemic sclerosis (SSc) is the most severe of the systemic autoimmune diseases. It is characterized by skin and organ fibrosis (mainly interstitial lung disease, which affects 40-50% of patients), as well as severe vascular complications such as pulmonary hypertension (5-10%), renal crisis (2%), and digital gangrene (5%). There are currently no validated prognostic biomarkers for the progression of SSc, yet it is crucial to better predict the progression of SSc to optimize patient management, but also to identify the optimal population for clinical trials ("progressor" patients). Furthermore, there are no validated biomarkers of response to immunosuppressive therapies that would be useful both in patient management and in the evaluation of new treatments in clinical trials. The internal medicine department of the Lille University Hospital is a national and European reference center for the management of patients with SSc. Nearly 500 patients are followed annually in the internal medicine department. As part of their routine care, patients are hospitalized in average once a year in the internal medicine department of the Lille University Hospital for a complete assessment of their SSc. This assessment includes a detailed medical observation, complementary examinations and blood and urine biology tests. The purpose of this study would be to collect 2 additional blood samples during the standard evaluation of scleroderma patients. The main objective of this collection of biological samples for scientific research will be the identification of new biomarkers associated with prognosis and treatment response to improve the management of SSc patients.
- Állapot (regiszter)
- Visszavonva
- Vizsgálattípus
- Megfigyeléses
- Résztvevők száma
- 0 (tényleges)
- Első benyújtás
- 2021. júl. 22.
- Kezdés
- 2023. ápr.
- Elsődleges befejezés
- 2043. ápr.
- Fő szponzor
- University Hospital, Lille
- Betegségek
- Szisztémás szklerózis (szkleroderma)
- NCT-szám
- NCT04986514
Ki nem vehet részt
Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.
Egyéb
- Administrative reasons: unable to receive informed information, lack of social security coverage
- Pregnant or lactating women
- Persons deprived of liberty
- Minors or protected adults
- Persons who have refused or are unable to give informed consent
- Persons in emergency situations
Kiket keres a vizsgálat
- Patient followed for SSc in the internal medicine or cardiology department of the Lille University Hospital
- Fulfilling the ACR/EULAR and/or VEDOSS criteria for SSc
- Being insured by the French social security system
- Having the ability to understand the requirements of the study and provide informed consent
Életkor a regiszterben: 18 év – - · Nem: nők és férfiak · Egészséges önkénteseket nem fogad
Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.